Bioverativ Therapeutics Inc.
Bioverativ Therapeutics Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for patients with rare blood disorders. Founded in 2017, Bioverativ has quickly established itself in the biopharmaceutical industry, particularly in the areas of haemophilia and other blood-related conditions. The company’s core products, including its advanced therapies for haemophilia A and B, are distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Bioverativ's dedication to research and development has positioned it as a key player in the market, achieving significant milestones in clinical trials and product launches. With a strong emphasis on patient-centric solutions, Bioverativ continues to make strides in transforming the treatment landscape for individuals with bleeding disorders.
DitchCarbon Score
How does Bioverativ Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioverativ Therapeutics Inc.'s score of 55 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bioverativ Therapeutics Inc.'s reported carbon emissions
Bioverativ Therapeutics Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their carbon footprint in terms of kg CO2e across Scope 1, 2, or 3 emissions. In the absence of specific emissions data, it is important to note that many companies in the biopharmaceutical sector are increasingly committing to sustainability initiatives and climate action. While Bioverativ has not disclosed any formal climate commitments or reduction initiatives, the industry trend leans towards setting science-based targets and enhancing transparency in emissions reporting. As the company continues to operate within this evolving landscape, stakeholders may look for future announcements regarding their climate strategies and potential commitments to reducing their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bioverativ Therapeutics Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
